MacDonald Center for Nutrition Education and Research (MCNER) Webinar Series for Health Professionals



Metabolic Shifts and Menopause: The Role of Diet in Women's Midlife Health

Wednesday, September 17, 2025

Presented by Hannah Cabré, PhD, RDN



Moderator: Lisa Diewald, MS, RDN, LDN Associate Director

MacDonald Center for Nutrition Education and Research

Finding slides for today's webinar



- Slides are posted at villanova.edu/cope
- From right menu→ Webinars
- Go to 9/17/25 webinar presented by Hannah Cabré, PhD, RDN

Continuing Professional Development Details



- Villanova University M. Louise Fitzpatrick College of Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity awards I contact hour for nursing professionals.
- This activity awards 1 CPEU in accordance with the Commission on Dietetic Registration's CPEU Prior Approval Program
 - Level 2 activity
 - Suggested CDR Performance Indicators: 7.1.1, 7.2.3, 9.1.1, and 9.1.5
 - To receive CE credit, you must attend the entire program.

The Q&A Box is Open!



- Questions are welcome!
- Please send through the Q&A Box during the presentation.
- Q&A session will follow the program.

Disclosures



Dr. Cabré has received research funding from the National Pork Board. The relevant financial relationships listed for this individual have been mitigated.

Planners will review participant feedback to evaluate for real or perceived commercial bias in any activity.



Hannah Cabré, PhD, RDN
Postdoctoral Research Fellow
Reproductive Endocrinology and Women's
Health Laboratory
Pennington Biomedical Research Center



MacDonald

CENTER FOR NUTRITION EDUCATION AND RESEARCH

Metabolic Shifts and Menopause: The Role of Diet in Women's Midlife Health

Presented by Hannah Cabré, PhD, RDN

Metabolic Shifts and Menopause: The Role of Diet in Women's Midlife Health

Hannah E. Cabre, PhD, RDN
Postdoctoral Research Fellow
Pennington Biomedical Research Center



Disclosures

Funding from the National Pork Board

Objectives

- Understand the physiological and behavioral changes that surround the transition from normal menstrual cycle function to menopause
- Describe the impact of estrogen loss from clinical studies on female metabolism and weight gain.
- Summarize the specific nutritional and health needs to optimize health post-menopause and the interventions with established efficacy
- Introduce precision nutrition approaches tailored to midlife women

Women Have Been Misled About Menopause

Hot flashes, sleeplessness, pain during sex: For some of menopause's worst symptoms, there's an established treatment. Why aren't more women offered it?

By Susan Dominus

Feb. 1, 2023

'Menopause has the worst P.R. campaign in the history of the universe, because it's not just hot flashes and night sweats.'

'It suggests that we have a high cultural tolerance for women's suffering. It's not regarded as important.'



Administration

NOVEMBER 17, 2023

Launch of White House Initiative on Women's Health Research

April 6, 2021

"We get 'the talk' before we start our periods around the end of grade school, but nobody gives you 'the talk' when you're about to enter perimenopause."

 Dr. Stephanie S. Faubion, medical director for the North American Menopause Society




Study Shows the Staggering Cost of Menopause for Women in the Work Force The New York Times Magazine

Some are taking sick days. Others are cutting back their hours. Still others end up quitting altogether.

\$1.8 Billion in lost working time per year

Weight gain is one of the most common concerns among women going through menopause. New drugs could change that.






How do hormones change across the lifespan?

↑ Risk of Osteoporosis

Pre-menopause: regular menstrual cycles


Peri-menopause: irregular menstrual cycles (but not amenorrheic for <12 months); mean onset: 44 yrs

Post-menopause: amenorrheic for ≥ 12 months; **mean age 51 yrs**





Reproductive Endocrine Changes




Menarche FMP (0)											
Stage	-5	-4	-3b	-3a	-2	-1	+1a	+1b	+1c	+2	
		REPROI	DUCTIVE		MENOPAUSAL	TRANSITION	POSTMENOPAUSE				
Terminology	Early	Peak	I	Late	Early	Late		Ear	ly	Late	
					Perin	nenopause					
Duration		var	iable		variable	1-3 years	_	ears +1)	3-6 years	Remaining lifespan	
PRINCIPAL CI	RITERIA										
Menstrual Cycle	Variable to regular	Regular	Regular	Subtle changes in Flow/ Length	Variable Length: Persistent ≥7-day difference in length of consecutive cycles	Interval of amenorrhea of ≥60 days					
SUPPORTIVE	CRITERIA										
Endocrine FSH AMH Inhibin B			Low Low	Variable * Low Low	↑ Variable * Low Low	↑>25 IU/L ** Low Low	L	iable * ow ow	Stabilizes Very Low Very Low		
Antral Follicle Count			Low	Low	Low	Low	Very	Low	Very Low		
DESCRIPTIVE	CHARAC	TERISTIC	CS								
Symptoms						Vasomotor symptoms <i>Likely</i>	symp	motor otoms Likely		Increasing symptoms of urogenital atrophy	



Greendale GA et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 7;4(5):e124865. doi: 10.1172/jci.insight.124865.

Timing of Menopause Onset & Health Consequences





Characteristics of the 771 participants at baseline and at the end of follow-up, CARDIA study 1990-1991 to 2015-2016

Racolina

		Baseiine	Ena of follow-up
	Characteristics	(Premenopausal)	(Postmenopausal)
	Age, years	31.8 (2.9)	56.4 (3.1)
	Systolic blood pressure, mmHg	103.4 (10.4)	117.7 (17.2)
	Anti-hypertensive medication use, %	1.7	28.5
	Diabetes, %	0.1	11.8
	Physical activity, exercise units	330 (250)	292 (241)
	Body mass Index, kg/m ²	25.5 (6.4)	29.9 (7.8)
	Waist circumference, com	76.9 (12.5)	90.8 (16.9)
	Lipid-lowering medication use, %	0.3	17.8
1	HDL cholesterol, mg/dL	58.4 (13.6)	67.8 (18.7)
	Total cholesterol, mg/dL	176.5 (30.6)	201.1 (35.6)

Exponential Increase in Diseases




End of follow up



Sex Differences Across Age Groups

eBioMedicine
Pand THE LANCET Drawny Stance
Pand THE LANCET Drawny


- The ZOE PREDICT I UK study (1,002 females and 247 males)
- Phenotypic characteristics, diet, and cardiometabolic measurements





Menopause is Associated with Metabolic Health





- The ZOE PREDICT I UK study (n=1,002)
- Postmenopausal women demonstrated unfavorable outcomes compared to premenopausal women


■ Premenopause (n=359) ■ Perimenopause (n=55) ■ Postmenopause (n=205)



Age-Matched Inter-Individuality











The Menopause Transition is Complex


Demographic Factors



Physiological Factors




Time of Transition



Behavioral Factors




Change in percent body fat is reflected by loss of fat-free mass





Body Composition Changes Across Age




Role of Estrogen

Hormone replacement therapy research suggests that the delivery of **estrogen** may attenuate or even reverse the age-related decline in lean mass in postmenopausal women



Estrogen & Body Composition Changes






- Nationwide multi-ethnic study (n=1,246) (Greendale et al. 2019)
- Approximately 10 years of annual testing via **DXA**
- A 4-compartment study across age


Table 2. Body Composition by Decade of Age (kg, mean \pm SD)

Age	No. of Subjects	Protein	· Water	Mineral	Fat
20-30	8	9.9 ± 0.8	33.2 ± 2.0	2.9 ± 0.3	14.6 ± 5.5
31-40	29	9.2 ± 0.8	31.5 ± 2.8	2.8 ± 0.3	19.7 ± 6.7 ↑
41-50	44	9.1 ± 0.8	31.4 ± 3.6	2.8 ± 0.3	24.2 ± 7.1
51-60	25	8.8 ± 1.0	30.4 ± 3.8	2.6 ± 0.4	23.4 ± 7.2
61-70	35	8.4 ± 1.0	30.0 ± 3.9	2.4 ± 0.3	24.8 ± 7.3
71-80	14	8.4 ± 0.9	29.3 ± 3.8	2.2 ± 0.3	21.5 ± 6.8
Overall	155	8.9 ± 1.0	30.9 ± 3.5	2.6 ± 0.4	22.6 ± 7.3




Aging Effects Total Daily Energy Expenditure








Estrogen & Energy Expenditure




- 9% ↓ in TEE in postmenopausal women (Lovejoy et al. 2008)
 - 9% ↓ in SEE (~111 kcal/day)
 - ↓ in fat oxidation





Menopause symptoms impact health outcomes



% body fat was significantly positive correlation with menopause symptoms (r=0.464) and inversely correlated with steps (r=-0.364) and vigorous activity (r=-0.239)



Lifestyle Behaviors

Physical Activity

- 50% ↓ in PA through the menopause transition
- PA ↑ in 30% of women who entered menopause
- Higher PA resulted in better physical function at 15-year follow up

Diet


- ↓ energy intake by **250-800 kcal/day** at menopause onset (food logs)
- ↑ saturated fat & ↑ cholesterol and ↓ carbohydrates

Sleep Quality


- † use of sleep medications in post-menopause
- 40-60% of menopausal women struggle with sleep problems
- Greater vasomotor symptoms → poorer sleep quality



Exercise Preferences Vary







Cardiometabolic Health Gastrointestinal Health Weight Gain & Decreased Metabolism · Magnesium-containing supplements · Supplementing calcium and vitamin B12 injections · Reduce calorie intake, increase physical activity (if warranted) Encourage healthy eating and portion control Weight · Utilize behavioral modifications (e.g., support Gain system, self-monitoring of weight and calorie Decreased GI Metabolism intake ≥5 days/week) **Bone Health Vasomotor** Bone **MENOPAUSE** · Promote dietary consumption of calcium-**Symptoms** Health rich foods, vitamins D and K, magnesium, and phosphorous · Consider supplementing calcium and vitamin D when intake is insufficient Social **Poor Physical Symptoms** Isolation Sleep Mood **Disorders** Vasomotor Symptoms (VMS) & Poor Sleep · Avoid caffeine, alcohol, and spicy foods · Dietary remedies may help with VMS (e.g., soy, black cohosh, and vitamin E) · Consuming a Mediterranean diet and other foods may promote sleep (e.g., milk, fish, and **Psychosocial Symptoms** cherry juice). Social Isolation Mood Disorders · Identify food insecurities Educate women on mental health · Discuss emotional eating

· Encourage calorie-controlled diet



Refer to local resources and services

Mediterranean Diet

- The FLAMENCO project in perimenopausal women (n=176)
- Mediterranean Diet Score on food frequency questionnaire





BMI and %body fat





BMI, waist circumference, total and android fat mass, %body fat, android to gynoid fat mass ratio, VAT





Body weight, BMI, waist circumference, total and android fat mass, VAT





Waist circumference and %body fat













Body weight, BMI, waist circumference, %body fat, total and android fat mass, VAT



Treatment Strategies

Caloric Reduction


- Declines in calories expended, physical activity, and fat burning capacity
- Reduce energy intake by focusing on portion sizes and nutrient dense foods
- Calorie deficit of 400-600 kcal/day is a general recommendation

Estimated Energy Requirement

- Women 19 years and older:
 EER = 354 (6.91 × age [y]) + PA × (9.36 × weight [kg] + 726 × height [m]),
 where PA is the estimated physical activity level ranging from 1 to 2.5 (sedentary to very active).
- No differences in energy needs based on race and menopause stage

Diet Quality and Exercise

- MyPlate for healthy eating pattern,
 Mediterranean Diet, and DASH diet
- Exercise is important for muscle mass and bone mineral retention





Exercise and Metabolic Profiles



Waist Circumference (cm)

	Exerci	C	ontrol			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Azadpour 2017	-1.4	4.4	12	0.5	3.66	12	3.5%	-1.90 [-5.14, 1.34]	
Bergström 2009	-1.6	3.61	48	-0.2	3.35	44	7.1%	-1.40 [-2.82, 0.02]	
Biteli 2021a	-3.5	5.9	24	-0.7	6.23	22	3.2%	-2.80 [-6.31, 0.71]	
Biteli 2021b	-7.3	6.71	11	0.3	6.21	13	1.8%	-7.60 [-12.81, -2.39]	
Chagas 2017	-4.7	0.92	35	-0.3	5.85	35	5.9%	-4.40 [-6.36, -2.44]	
Church 2007	-1.4	6.42	103	-1.4	6.59	102	6.3%	0.00 [-1.78, 1.78]	_
Colado 2009	-3.6	4.19	21	2.3	4.08	10	3.7%	-5.90 [-9.00, -2.80]	
Conceicao 2013	1.5	2	10	-0.3	5.02	10	3.4%	1.80 [-1.55, 5.15]	-
Dalleck 2009	-2.5	6.99	8	0.7	5.58	10	1.4%	-3.20 [-9.15, 2.75]	
Friedenreich 2011	-2.2	4.8	160	0.1	5.12	160	8.0%	-2.30 [-3.39, -1.21]	
3omez-Tomas 2018	-2.7	4.5	18	3.3	5.81	20	3.5%	-6.00 [-9.29, -2.71]	
Hettchen 2021	-2.9	3.9	27	-0.4	3.6	27	5.8%	-2.50 [-4.50, -0.50]	
Kim and Kim 2012	-1.2	0.72	15	0.9	0.84	15	9.0%	-2.10 [-2.66, -1.54]	-
Latosik 2014	-3.8	5.77	15	1	4.65	10	2.6%	-4.80 [-8.90, -0.70]	
Lee 2012	-1.3	0.72	8	0.4	0.96	8	8.5%	-1.70 [-2.53, -0.87]	-
Lesser 2016	-4	7.37	23	-0.8	7.34	26	2.5%	-3.20 [-7.33, 0.93]	
Nunes 2016	-4	5.44	11	4	5.31	11	2.2%	-8.00 [-12.49, -3.51]	
Senechal 2012	-0.7	4.9	10	-1.7	0.3	10	3.8%	1.00 [-2.04, 4.04]	
Seo 2010	-4.3	2.58	8	-0.9	2.38	7	4.7%	-3.40 [-5.91, -0.89]	
Son and Park 2021	-3.4	0.3	18	0.5	1.1	17	9.0%	-3.90 [-4.44, -3.36]	-
Trabka 2014	-1	4.82	23	0.1	4.71	21	4.2%	-1.10 [-3.92, 1.72]	
Total (95% CI)			608			590	100.0%	-2.62 [-3.39, -1.86]	•
Heterogeneity: Tau* = 1	1.62: Chi²	= 76.49	. df = 21) (P < 0.	00001); ² = 7	4%		- J. t 1 .t
Test for overall effect: 2									-10 -5 0 5 10 Favours [exercise] Favours [control]

Blood Glucose (mmol/L)

Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI I		Exerci	Control			Std. Mean Difference		Std. Mean Difference		
Biteli 2021b	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Chagas 2017	Biteli 2021a	-0.2	0.54	24	0.7	1.09	22	5.5%	-1.04 [-1.66, -0.42]	
Church 2007	Biteli 2021b	0.4	0.49	11	0.9	0.77	13	4.1%	-0.73 [-1.57, 0.10]	
Colado 2009	Chagas 2017	0.1	0.78	35	0.9	0.73	35	6.4%	-1.05 [-1.55, -0.55]	
Conceicao 2013	Church 2007	-0.1	0.3	103	0	0.37	102	8.3%	-0.30 [-0.57, -0.02]	
Dalleck 2009	Colado 2009	0.1	0.3	21	0.4	0.25	10	4.3%	-1.02 [-1.82, -0.22]	1
Frank 2005	Conceicao 2013	-0.8	0.45	10	-0.1	0.25	10	2.9%	-1.84 [-2.93, -0.76]	
Hettchen 2021	Dalleck 2009	-0.2	0.32	8	0.1	0.51	10	3.5%	-0.65 [-1.61, 0.31]	
Kim and Kim 2012	Frank 2005	0.1	3.04	87	0.1	2.66	86	8.1%	0.00 [-0.30, 0.30]	+
Lee 2012	Hettchen 2021	0.2	0.45	27	0.2	0.46	27	6.2%	0.00 [-0.53, 0.53]	+
Lesser 2016 -0.3 0.68 23 -0.1 0.54 26 5.9% -0.32 [-0.89, 0.24] Marcus 2009 0 0.24 10 -0.1 0.25 6 3.2% 0.39 [-0.64, 1.41] Miyaki 2012 0.2 0.24 11 0 0.25 11 3.9% 0.79 [-0.09, 1.66] Moreau 2001 -0.1 0.74 15 -0.1 0.72 9 4.1% 0.00 [-0.83, 0.83] Neves 2017 -0.1 1.05 27 0.4 0.91 19 5.7% -0.49 [-1.09, 0.10] Senechal 2012 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Kim and Kim 2012	-0.3	0.36	15	-0.3	0.38	15	4.8%	0.00 [-0.72, 0.72]	- 1-
Marcus 2009 0 0.24 10 -0.1 0.25 6 3.2% 0.39 [-0.64, 1.41] Miyaki 2012 0.2 0.24 11 0 0.25 11 3.9% 0.79 [-0.09, 1.66] Moreau 2001 -0.1 0.74 15 -0.1 0.72 9 4.1% 0.00 [-0.83, 0.83] Neves 2017 -0.1 1.05 27 0.4 0.91 19 5.7% -0.49 [-1.09, 0.10] Sene chal 2012 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI)	Lee 2012	-0.3	0.36	8	-0.3	0.38	8	3.4%	0.00 [-0.98, 0.98]	
Miyaki 2012 0.2 0.24 11 0 0.25 11 3.9% 0.79 [-0.09, 1.66] Moreau 2001 -0.1 0.74 15 -0.1 0.72 9 4.1% 0.00 [-0.83, 0.83] Neves 2017 -0.1 1.05 27 0.4 0.91 19 5.7% -0.49 [-1.09, 0.10] Sene 2010 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI)	Lesser 2016	-0.3	0.68	23	-0.1	0.54	26	5.9%	-0.32 [-0.89, 0.24]	
Moreau 2001 -0.1 0.74 15 -0.1 0.72 9 4.1% 0.00 [-0.83, 0.83] Neves 2017 -0.1 1.05 27 0.4 0.91 19 5.7% -0.49 [-1.09, 0.10] Senechal 2012 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16] ◆	Marcus 2009	0	0.24	10	-0.1	0.25	6	3.2%	0.39 [-0.64, 1.41]	
Neves 2017 -0.1 1.05 27 0.4 0.91 19 5.7% -0.49 [-1.09, 0.10] Senechal 2012 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Miyaki 2012	0.2	0.24	11	0	0.25	11	3.9%	0.79 [-0.09, 1.66]	
Senechal 2012 0.1 0.42 10 0.1 0.3 10 3.9% 0.00 [-0.88, 0.88] Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Moreau 2001	-0.1	0.74	15	-0.1	0.72	9	4.1%	0.00 [-0.83, 0.83]	
Seo 2010 -0.3 0.24 8 0.1 0.32 7 2.7% -1.35 [-2.50, -0.19] Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Neves 2017	-0.1	1.05	27	0.4	0.91	19	5.7%	-0.49 [-1.09, 0.10]	
Son and Park 2021 -0.2 0.12 18 0.1 0.5 17 5.0% -0.82 [-1.51, -0.12] van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Senechal 2012	0.1	0.42	10	0.1	0.3	10	3.9%	0.00 [-0.88, 0.88]	
van Gemert 2015 0 0.25 96 0 0.25 93 8.2% 0.00 [-0.29, 0.29] Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16] ◆	Seo 2010	-0.3	0.24	8	0.1	0.32	7	2.7%	-1.35 [-2.50, -0.19]	
Total (95% CI) 567 536 100.0% -0.38 [-0.60, -0.16]	Son and Park 2021	-0.2	0.12	18	0.1	0.5	17	5.0%	-0.82 [-1.51, -0.12]	
	van Gemert 2015	0	0.25	96	0	0.25	93	8.2%	0.00 [-0.29, 0.29]	+
Heterogeneity: Tau² = 0.14; Chi² = 51.13, df = 19 (P < 0.0001); P= 63%	Total (95% CI)			567			536	100.0%	-0.38 [-0.60, -0.16]	•
	Heterogeneity: Tau ² =	0.14; Ch	P= 51.1	3. df = 1	19 (P «	0.0001); P= 6	3%		
Test for overall effect: Z = 3.33 (P = 0.0009) -4 -2 0 2 Favours [exercise] Favours [control]					4		****	Selection.		-4 -2 0 2 4






Regular physical activity can be a non-pharmacological tool in reduction of metabolic syndrome in postmenopausal women



Caloric Restriction

JAMA Network Open

- The TEMPO Diet Trial in postmenopausal women (n=101)
- 12-month diet intervention
 - Moderate CR (25-35%)
 - 4-mo. severe CR (65-75%) +
 8-mo. Moderate
 - Both groups 1.0 g/kg protein
- Both interventions were effective for weight loss, but sever CR decreased lean body mass and bone mineral density to a greater extent







Diet or Exercise

Breast Cancer Research





- 16-week intervention
 - Calorie-reduced (-500 kcal/d)
 - Intensive aerobic + resistance training program (-250 kcal/d)
 - Control group
- Aerobic exercise paired with resistance training and slight caloric restriction preserves lean mass while decreasing weight and fat mass






Caloric Restriction + Exercise




- Postmenopausal women (n=439)
- 12-month diet intervention
 - Calorie-reduced, low-fat diet
 - Moderate-intensity aerobic exercise
 - Combination of diet + exercise
- Changes in diet drive body composition changes
- The addition of exercise maximizes intervention efficacy





The New Frontier: Precision Nutrition





Summary

- The loss of estrogen leads to body composition changes which drive adverse metabolic outcomes in postmenopausal women
- Menopausal symptoms impact quality of life and are related to body composition and exercise habits
- Caloric restriction with exercise can attenuate negative body composition changes and improve metabolic profiles





Mentors & Colleagues

Leanne Redman, PhD
Eric Ravussin, PhD
Steve Heymsfield, PhD
Abbie Smith-Ryan, PhD
Anthony Hackeny, PhD
Kara Marlatt, PhD
Lacey Gould, MS
Sam Moore, MS



Amazing Lab Team

Abby Altazan (Lab Manager)

Madison Dickey (Clinical Res Specialist)

Taylor Lejune (Clinical Res Specialist)

Ariel Barlow (Clinical Res Specialist)

Ava Ames (Clinical Res Specialist)

Erin Bunch (Clinical Res Specialist)

Charlotte Norman (Clinical Res Specialist)

Jada Butler (Clinical Res Specialist)

Kimberly Billiot (Clinical Res Specialist)

Em Simeon (Interventionist)

Julie Hardee (Interventionist)

Caitlin Hebert (Research Specialist)

Alexandra Nauta (Assistant to AED)

References

- 1. Greendale GA et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 7;4(5):e124865. doi: 10.1172/jci.insight.124865.
- 2. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008 Jun;32(6):949-58. doi: 10.1038/ijo.2008.25. Epub 2008 Mar 11.
- 3. Gould LM, Gordon AN, Cabre HE, Hoyle AT, Ryan ED, Hackney AC, Smith-Ryan AE. Metabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism. Menopause. 2022 Feb 28;29(4):377-389. doi: 10.1097/GME.000000000001932.
- 4. Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB, Vuga M. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011 Mar;96(3):746-54. doi: 10.1210/jc.2010-1746. Epub 2010 Dec 15. PMID: 21159842; PMCID: PMC3047231.
- 5. Chidi-Ogbolu N and Baar K (2019). Effect of Estrogen on Musculoskeletal Performance and Injury Risk. Front. Physiol. 9:1834. doi: 10.3389/fphys.2018.01834
- 6. Appiah D et al. The association of age at natural menopause with pre- to postmenopausal changes in left ventricular structure and function: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Menopause. 2022;29(5):564-572. doi: 10.1097/GME.000000000001950.
- 7. Bermingham KM, et al.. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303.
- 8. Van Pelt RE, Gavin KM, Kohrt WM. Regulation of Body Composition and Bioenergetics by Estrogens. Endocrinol Metab Clin North Am. 2015Sep;44(3):663-76. doi: 10.1016/j.ecl.2015.05.011.
- 9. Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135-170. doi:10.1016/bs.apcsb.2019.01.001.
- 10. Enns DL, Tiidus PM. The influence of estrogen on skeletal muscle: sex matters. Sports Med. 2010 Jan 1;40(1):41-58. doi:10.2165/11319760-000000000-00000.
- 11. Sorensen MB, Rosenfalck AM, Hojgaard L, et al. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001; 9:622-6
- 12. Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 Mar 7;4(5):e124865. doi: 10.1172/jci.insight.124865.
- 13. Moore SR, Cabre HE, Smith-Ryan AE. Body composition, physical activity, and menopause symptoms: how do they relate? Menopause. 2024 Apr 1;31(4):336-341. doi: 10.1097/GME.0000000000002334.
- 14. Hulteen RM, Marlatt KL, Allerton TD, Lovre D. Detrimental Changes in Health during Menopause: The Role of Physical Activity. Int J Sports Med. 2023 Jun;44(6):389-396. doi: 10.1055/a-2003-9406. Epub 2023 Feb 17. PMID: 36807278; PMCID: PMC10467628.
- 15. Moilanen JM, Aalto AM, Raitanen J, Hemminki E, Aro AR, Luoto R. Physical activity and change in quality of life during menopause--an 8-year follow-up study. Health Qual Life Outcomes. 2012 Jan 23;10:8. doi: 10.1186/1477-7525-10-8. PMID: 22269072; PMCID: PMC3311608.
- 16. Duval K, Prud'homme D, Rabasa-Lhoret R, Strychar I, Brochu M, Lavoie JM, Doucet E. Effects of the menopausal transition on dietary intake and appetite: a MONET Group Study. Eur J Clin Nutr. 2014 Feb;68(2):271-6. doi: 10.1038/ejcn.2013.171. Epub 2013 Sep 25. PMID: 24065065; PMCID: PMC4954773.
- 18. Maki, Pauline M. PhD1; Panay, Nick BSc, FRCOG2; Simon, James A. MD, MSCP3. Sleep disturbance associated with the menopause. Menopause 31(8):p 724-733, August 2024. | DOI: 10.1097/GME.000000000000386
- 19. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann NY Acad Sci. 2000 May;904:502-6. doi:10.1111/j.1749-6632.2000.tb06506.x.
- 20. Marlatt KL, Redman LM, Beyl RA, Smith SR, Champagne CM, Yi F, Lovejoy JC. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol. 2020 Apr;222(4):365.e1-365.e18. doi:10.1016/j.ajog.2019.09.051.
- 21. Marlatt KL, Gilmore LA, Flanagan EW, Redman LM. Dietary Considerations for Postmenopausal Women. Nutrient Guide for Physicians and Related Healthcare Professions. 2020. Nutrition and Health.
- 22. Seimon RV et al. Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial. JAMA Netw Open. 2019 Oct2;2(10):e1913733. doi: 10.1001/jamanetworkopen.2019.13733.
- 23. Flor-Alemany M, Marín-Jiménez N, Nestares T, Borges-Cosic M, Aranda P, Aparicio VA. Mediterranean diet, tobacco consumption and body composition during perimenopause. The FLAMENCO project. Maturitas. 2020 Jul;137:30-36. doi: 10.1016/j.maturitas.2020.04.002.
- 24. van Gemert WA, Schuit AJ, van der Palen J, May AM, Iestra JA, Wittink H, Peeters PH, Monninkhof EM. Effect of weight loss, with or without exercise, on body composition and sex hormones in postmenopausal women: the SHAPE-2 trial. Breast Cancer Res. 2015 Sep 2;17(1):120. doi: 10.1186/s13058-015-0633-9.
- 25. Kohrt WM, Snead DB, Slatopolsky E, Birge SJ Jr. Additive effects of weight-bearing exercise and estrogen on bonemineral density in older women. J Bone Miner Res. 1995 Sep;10(9):1303-11. doi: 10.1002/jbmr.5650100906.
- 26. Tan A, Thomas RL, Campbell MD, Prior SL, Bracken RM, Churm R. Effects of exercise training on metabolic syndrome riskfactors in post-menopausal women A systematic review and meta-analysis of randomised controlled trials. Clin Nutr. 2023Mar;42(3):337-351. doi: 10.1016/j.clnu.2023.01.008.
- 27. Foster-Schubert KE, Alfano CM, Duggan CR, Xiao L, Campbell KL, Kong A, Bain CE, Wang CY, Blackburn GL, McTiernan A. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity (Silver Spring). 2012 Aug;20(8):1628-38. doi: 10.1038/oby.2011.76.
- 28. Cabre HE, Woolf EK, Redman LM. Precision Nutrition for Management of Cardiovascular Disease Risk during Menopause. Lifestyle Genom. 2024;17(1):93-101. doi: 10.1159/000540337. Epub 2024 Jul 24. PMID: 39047690; PMCID: PMC11394930.

Pennington Biomedical Research Center

labs.pbrc.edu/womenshealth

- f /penningtonbiomedical
- @HannahCabreRD
- /penningtonbiomedical
- @hannahcabre_phd

To Receive Your CE Certificate



- A link to an evaluation will be sent within a day or two.
- RNs must complete the evaluation to receive CE certificate.
- RD/RDNs: Although completing an evaluation is not required, we truly appreciate your feedback.
 - If you do not see the evaluation, look in your spam folder.
- CE certificates for RDs/RDNs/DTRs will be emailed within 2 business days after the program.

Upcoming MCNER Webinars



Nourishing Our Neighbors: Connecting Hunger Relief, Nutrition Education, and Health

Lauren Duff, Chief Public Affairs Officer Megan Greevy, MS, RD, LDN, Director of Nutrition Education Feeding Pennsylvania

> Wednesday, 10/29/25 12-1 PM ET

> > To Register:

MacDonald Center for Nutrition Education and Research website

1 free CPEU RDs/DTRs

Upcoming MCNER Health Professional Webinars



Dietary Fiber: How Much, Why It Matters for Gut Health and How to Bridge the Gap

Nicola McKeown, PhD with Rodney Wallace, PhD and P. Stephen Baezinger, PhD

> Wednesday, 11/12/25 12-1 PM ET

> > To Register:

MacDonald Center for Nutrition Education and Research website

1 Free contact hour RNs/Nurse Practitioners 1 free CPEU RDs/DTRs

Q&A

Moderator:
Lisa Diewald, MS, RDN, LDN
mcner@villanova.edu

If you are an RD or RDN and have any questions or concerns about this continuing education activity, you may contact CDR directly at QualityCPE@eatright.org.

